杜皮卢马布在阿托皮性皮肤炎患者:一个多中心,长期,现实世界的葡萄牙研究
Tiago Torres1,2, Maria João Cruz3, Margarida Gonçalo4
1Department of Dermatology, CAC ICBAS-CHP - Centro Académico Clínico ICBAS - CHP, Porto, Portugal. torres.tiago@outlook.com.
Dermatology and therapy
|July 22, 2024
概括
这项研究表明,dupilumab在现实环境中对皮炎 (AD) 有效且安全,在30个月内药物存活率高,症状明显改善.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 杜皮卢马布在治疗亚托皮性皮炎 (AD) 的确定的疗效和安全性.
- 关于阿兹海默症患者长期杜皮卢马布疗效,安全性和药物存活率的有限现实数据.
研究的目的:
- 在现实环境中评估dupilumab在AD成人患者的长期有效性,安全性和药物存活率.
主要方法:
- 对312名开始使用dupilumab的AD患者进行了回顾性,多中心的观察性研究.
- 随访时间长达30个月,评估药物存活率,不良事件,湿疹区域和严重程度指数 (EASI),的数值评分表 (NRS) 和皮肤病生命质量指数 (DLQI).
主要成果:
- 30个月药物存活率为82.0%.
- 观察到显著改善:EASI (89.3%),性NRS (76.4%) 和DLQI (85.2%) 在30个月后.
- 最常见的不良事件是结膜炎 (17%) 和面部红斑 (9%);12.5%的人停止治疗.
结论:
- 杜皮卢马布在现实临床实践中证明了AD管理的持续有效性和有利的安全性.
- 这项研究为超越受控临床试验的长期dupilumab结果提供了有价值的数据.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880


